Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer

Summary

The number of NSCLC patients above 70 years of age who are non-squamous histology is increasing around the world. Although previous guidelines often recommend single agent therapy for NSCLC, recent studies suggest that platinum doublets may be better than standard monotherapy in elderly. We hypothesize that for elder patients (≥70 years of age) with non-squamous NSCLC, pemetrexed and carboplatin is more effective than pemetrexed monotherapy in terms disease progression, overall survival, and quality of life and tolerability.

Timeline

Start

2012-03

Primary completion

2014-11

Completion

2015-11

Drugs

Indications